CLYM
HEALTHCAREEliem Therapeutics Inc
$12.22+0.77 (+6.72%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CLYM Today?
No stock-specific AI insight has been generated for CLYM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.13$12.48
$12.22
Fundamentals
Market Cap$584M
P/E Ratio—
EPS$-0.88
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding47.8M
CLYM News
20 articles- Climb Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLEMarketbeat·May 5, 2026
- Climb Bio (CLYM) Enters Agreement for $110M Private Placement FinancingYahoo Finance·May 5, 2026
- Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data ReadoutsYahoo Finance·May 5, 2026
- Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026Yahoo Finance·May 1, 2026
- Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney DiseaseYahoo Finance·Apr 29, 2026
- Climb Bio, Inc. Announces $110.0 Million Private PlacementYahoo Finance·Apr 28, 2026
- FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?Yahoo Finance·Apr 20, 2026
- Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026Yahoo Finance·Apr 8, 2026
- Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous NephropathyYahoo Finance·Apr 7, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
- Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026Marketbeat·Mar 14, 2026
- Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 5, 2026
- Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer ConferenceMarketbeat·Feb 26, 2026
- Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at SummitMarketbeat·Feb 13, 2026
- Climb Bio to Present at Upcoming Investor ConferencesYahoo Finance·Feb 5, 2026
- Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value EstimateYahoo Finance·Jan 24, 2026
- Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026Yahoo Finance·Jan 8, 2026
- H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical TracksYahoo Finance·Dec 31, 2025
- Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn SituationYahoo Finance·Dec 28, 2025
All 20 articles loaded
Price Data
Open$11.48
Previous Close$11.45
Day High$12.24
Day Low$11.31
52 Week High$12.48
52 Week Low$1.13
52-Week Range
$1.13$12.48
$12.22
Fundamentals
Market Cap$584M
P/E Ratio—
EPS$-0.88
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding47.8M
About Eliem Therapeutics Inc
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—